Skip to main content
Top

20-05-2025 | GLP-1 Receptor Agonists | Podcast

Episode 19

GLP-1 medicines - past, present, and future

From diabetes to obesity and beyond

print
PRINT
insite
SEARCH
Guest:
Prof. Daniel Drucker
Hosts:
Dr. Natalie Wood
Claire Greenhill

In 2005 the US FDA approved the first GLP-1 medicine for type 2 diabetes, marking the start of a remarkable journey that goes beyond the stimulation of insulin secretion.

Prof. Daniel Drucker gives us a fascinating insight into the early work on GLP-1 and discusses how these medicines are impacting the lives of people with diabetes and obesity. He covers what's known about how they work, treatment duration, side effects, and the role of bariatric surgery, plus what's in the pipeline in terms of drug development and the indications that GLP-1 medicines may be used to treat in the future.

Read the transcript

« Previous episode: Episode 18: The fight for children's eyesight

Further reading

print
PRINT

Related topics